{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:43:55Z","timestamp":1792122235480,"version":"4.4.0"},"reference-count":73,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7) represents a potential target for CAR T-cell therapy in the treatment of multiple myeloma (MM), and it is a promising alternative to classic BCMA-CAR therapy. The receptor is expressed on immune cells, particularly natural killer cells and T cells, that can trigger both activating and inhibitory signals. It is highly expressed in MM cells at all disease stages, playing a crucial role in cell adhesion and communication between immune cells, and being involved in the development and progression of the disease. The target has a proven clinical success with Elotuzumab (anti-SLAMF7 antibody); it works by activating immune cells to kill myeloma cells, and limited expression on normal tissues, with, potentially, few side effects. SLAMF7\u2019s combination of specificity, stability, and clinical validation makes it an excellent target for current and future MM therapies. However, \u2018fratricide death\u2019, a phenomenon where the engineered CAR-T cells attack and kill each other, is a critical issue that requires safe engineering solutions. In this work, we will provide an overview on the field with a specific focus on SLAMF7 as an emerging CAR-T cell target in MM.<\/jats:p>","DOI":"10.3390\/cancers17213471","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:16:24Z","timestamp":1761729384000},"page":"3471","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma"],"prefix":"10.3390","volume":"17","author":[{"given":"Caterina","family":"Alati","sequence":"first","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-4141","authenticated-orcid":false,"given":"Martina","family":"Pitea","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-349X","authenticated-orcid":false,"given":"Gaetana","family":"Porto","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2684-9269","authenticated-orcid":false,"given":"Erica","family":"Bilardi","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Bruna","family":"Greve","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda Donatella","family":"Vincelli","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rizzuto","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5857-7247","authenticated-orcid":false,"given":"Giorgia","family":"Policastro","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Alvaro","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Utano","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrio","family":"Gerace","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-8239","authenticated-orcid":false,"given":"Alessandro","family":"Allegra","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Piro","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Dulbecco University Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7258-475X","authenticated-orcid":false,"given":"Marco","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Dulbecco University Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"103193","DOI":"10.1016\/j.eclinm.2025.103193","article-title":"Global landscape and trends in lifetime risks of haematologic malignancies in 185 countries: Population-based estimates from GLOBOCAN 2022","volume":"83","author":"Sun","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1016\/S2352-3026(25)00117-6","article-title":"Optimising T-cell immunotherapy in patients with multiple myeloma: Practical considerations from the European Myeloma Network","volume":"12","author":"Moreau","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: Updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1158\/1078-0432.CCR-24-4181","article-title":"FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma","volume":"31","author":"Sharma","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-Term (\u22655-Year) Remission and Survival After Treatment with Ciltacabtagene Autoleucel in CARTITUDE-1 Patients with Relapsed\/Refractory Multiple Myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","article-title":"FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma","volume":"30","author":"Natrajan","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_9","unstructured":"(2021, April 08). Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Myeloma. NIH, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"ref_10","first-page":"2420","article-title":"Functional cure and long-term survival in multiple myeloma: How to challenge the previously impossible","volume":"109","author":"Engelhardt","year":"2024","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7891","DOI":"10.3390\/curroncol30090573","article-title":"SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments","volume":"30","author":"Chu","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2147\/DDDT.S98053","article-title":"Clinical potential of SLAMF7 antibodies-focus on elotuzumab in multiple myeloma","volume":"11","author":"Friend","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.critrevonc.2013.04.003","article-title":"CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma","volume":"88","author":"Veillette","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/s41375-022-01559-4","article-title":"CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells","volume":"36","author":"Ritchey","year":"2022","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"110574","DOI":"10.1016\/j.clim.2025.110574","article-title":"The role of signaling lymphocytic activation molecule (SLAM) family receptors in health and disease progression: Focusing on cancer and therapy","volume":"280","author":"Luo","year":"2025","journal-title":"Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Farhangnia, P., Ghomi, S.M., Mollazadehghomi, S., Nickho, H., Akbarpour, M., and Delbandi, A.A. (2023). SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1174138"},{"key":"ref_17","first-page":"74","article-title":"Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.3324\/haematol.2020.276402","article-title":"European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma","volume":"106","author":"Bruno","year":"2021","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in Multiple Myeloma: Current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the Antigen Density Requirement for CAR T-cell Activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Grywalska, E., Sosnowska-Pasiarska, B., Smok-Kalwat, J., Pasiarski, M., Nied\u017awiedzka-Rystwej, P., and Roli\u0144ski, J. (2020). Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy. Cells, 9.","DOI":"10.3390\/cells9040983"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Mishra, A.K., Gupta, A., Dagar, G., Das, D., Chakraborty, A., Haque, S., Prasad, C.P., Singh, A., Bhat, A.A., and Macha, M.A. (2023). CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond. Vaccines, 11.","DOI":"10.3390\/vaccines11111721"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3324\/haematol.2020.266841","article-title":"BCMA loss in the epoch of novel immunotherapy for multiple myeloma: From biology to clinical practice","volume":"108","author":"Zhou","year":"2023","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ejh.14101","article-title":"Antigen loss following CAR-T cell therapy: Mechanisms, implications, and potential solutions","volume":"112","author":"Mishra","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_27","first-page":"418","article-title":"Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transpl. Cell. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tedder, B., and Bhutani, M. (2025). Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma. Cells, 14.","DOI":"10.3390\/cells14141077"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Shen, C., Zhang, Z., and Zhang, Y. (2020). Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies. Biomed. Res. Int., 2020.","DOI":"10.1155\/2020\/8765028"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40164-024-00490-x","article-title":"Challenges and strategies associated with CAR-T cell therapy in blood malignancies","volume":"13","author":"Liu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100796","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: An update and perspective","volume":"59","author":"Nussinov","year":"2021","journal-title":"Drug Resist. Updates"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jtct.2025.07.009","article-title":"The fire or the forest: Untangling the role of inflammation and bone marrow health in CAR-T outcomes in acute lymphoblastic leukemia","volume":"31","author":"Valtis","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.7150\/thno.76854","article-title":"Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Theranostics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: Unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Cho, S.F., Xing, L., Anderson, K.C., and Tai, Y.T. (2021). Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13236136"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4274\/balkanmedj.galenos.2025.2025-4-25","article-title":"Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods","volume":"42","author":"Vural","year":"2025","journal-title":"Balkan Med. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","article-title":"Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma","volume":"14","author":"Larson","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0000000000000505","article-title":"Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host","volume":"47","author":"Zhou","year":"2024","journal-title":"J. Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","article-title":"NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e70764","DOI":"10.1002\/cam4.70764","article-title":"Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma","volume":"14","author":"Yan","year":"2025","journal-title":"Cancer Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2174\/0118715206350342241224073809","article-title":"A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy","volume":"25","author":"Mahalleh","year":"2025","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Moares, N., Gonzalez-Garcia, P., Yi-He, W., Mu\u00f1oz-Miranda, J.P., Gabucio, A., Luna-Espejo, R., Oca\u00f1a-Cuesta, J., Fernandez-Cisnal, R., Fernandez-Ponce, C.M., and Garcia-Cozar, F. (2025). Dual targeting of BCMA and SLAMF7 with the CARtein system: Chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1613222"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e29997","DOI":"10.1016\/j.heliyon.2024.e29997","article-title":"From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma","volume":"10","author":"Zhao","year":"2024","journal-title":"Heliyon"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_46","first-page":"e65291","article-title":"Current Strategies to Improve Chimeric Antigen Receptor T (CAR-T) Cell Persistence","volume":"16","author":"Ghorai","year":"2024","journal-title":"Cureus"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_48","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/hematology.2024000534","article-title":"Late complications and long-term care of adult CAR T-cell patients","volume":"2024","author":"Bishop","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-025-01225-9","article-title":"Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: A report from the UK National CAR T Panel","volume":"15","author":"Dulobdas","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e20230903","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and nex Tea Gogishvili, t-generation strategies","volume":"221","author":"Khericha","year":"2024","journal-title":"J. Exp. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2483613","DOI":"10.1080\/20565623.2025.2483613","article-title":"CAR-T cell therapies: Patient access and affordability solutions","volume":"11","year":"2025","journal-title":"Future Sci. OA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_55","unstructured":"(2021, April 08). Available online: https:\/\/clinicaltrials.gov\/study\/NCT03958656."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Kandra, P., Nandigama, R., Eul, B., Huber, M., Kobold, S., Seeger, W., Grimminger, F., and Savai, R. (2022). Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.903562"},{"key":"ref_57","unstructured":"(2021, April 08). Study Details | A Phase I\/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04499339."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: A first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0092-8674(00)80436-5","article-title":"Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells","volume":"91","author":"Ivics","year":"1997","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/mt.2010.2","article-title":"A transposon and transposase system for human application","volume":"18","author":"Hackett","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_61","first-page":"502","article-title":"Universal SLAMF7-specific CAR T-cells as treatment for multiple myeloma","volume":"130","author":"Mathur","year":"2017","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e008769","DOI":"10.1136\/jitc-2023-008769","article-title":"Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma","volume":"12","author":"Korst","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_63","unstructured":"(2021, April 08). Allogeneic CAR T-Cell Therapy UCARTCS1A Shows Promise for Multiple Myeloma. Available online: https:\/\/www.cgtlive.com\/view\/allogeneic-car-t-cell-therapy-ucartcs1a-shows-promise-for-multiple-myeloma."},{"key":"ref_64","unstructured":"(2021, April 08). FDA Lifts Clinical Hold on Study Evaluating UCARTCS1 for Myeloma. ASH Clinical News. American Society of Hematology. Available online: https:\/\/ashpublications.org\/ashclinicalnews\/news\/5433\/FDA-Lifts-Clinical-Hold-on-Study-Evaluating."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Lonez, C., and Breman, E. (2024). Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?. Cells, 13.","DOI":"10.3390\/cells13020146"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/leu.2017.302","article-title":"A compound chimeric antigen receptor strategy for targeting multiple myeloma","volume":"32","author":"Chen","year":"2018","journal-title":"Leukemia"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Geis, M., Nowotny, B., Bohn, M.D., Kouhestani, D., Einsele, H., Bumm, T., and Stuhler, G. (2021). Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments. Commun. Biol., 4.","DOI":"10.1038\/s42003-020-01558-0"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-0044-1785234","article-title":"CRISPR-Cas9 Gene Editing: Curing Genetic Diseases by Inherited Epigenetic Modifications","volume":"11","author":"Kolanu","year":"2024","journal-title":"Glob. Med. Genet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","article-title":"Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy","volume":"38","author":"Lei","year":"2024","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Seijas, A., Cora, D., Novo, M., Al-Soufi, W., S\u00e1nchez, L., and Arana, \u00c1.J. (2025). CRISPR\/Cas9 Delivery Systems to Enhance Gene Editing Efficiency. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202503.2038.v1"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3471\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:29:01Z","timestamp":1761730141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":73,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17213471"],"URL":"https:\/\/doi.org\/10.3390\/cancers17213471","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}